Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation epidemiological - Study in an unselected population

被引:54
作者
Caroli-Bosc, FX
Le Gall, P
Pugliese, P
Delabre, B
Caroli-Bosc, C
Demarquary, JF
Delmont, JP
Rampal, P
Montet, JC
机构
[1] Univ Nice, Hop Archet 2, Federat Malad Appareil Digest, F-06202 Nice 3, France
[2] Hop St Marguerite, INSERM, Hepatol Unit, Marseille, France
关键词
gallstones; HMG-CoA reductase inhibitors; fibrates;
D O I
10.1023/A:1005643014395
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation.
引用
收藏
页码:540 / 544
页数:5
相关论文
共 43 条
[1]   HMG-CoA reductase inhibitors and bile lithogenicity: Cholesterol supersaturation or nucleation defect? [J].
Ahmed, HA ;
Jazrawi, RP ;
Northfield, TC .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (03) :195-196
[2]   BILIARY LIPID-COMPOSITION DURING TREATMENT WITH DIFFERENT HYPOLIPEMIC DRUGS [J].
ANGELIN, B ;
EINARSSON, K ;
LEIJD, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (03) :185-190
[3]   CLOFIBRATE TREATMENT AND BILE CHOLESTEROL SATURATION - SHORT-TERM AND LONG-TERM EFFECTS AND INFLUENCE OF COMBINATION WITH CHENODEOXYCHOLIC ACID [J].
ANGELIN, B ;
EINARSSON, K ;
LEIJD, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1981, 11 (03) :185-189
[4]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[5]   A POPULATION STUDY ON THE PREVALENCE OF GALLSTONE DISEASE - THE SIRMIONE STUDY [J].
BARBARA, L ;
SAMA, C ;
LABATE, AMM ;
TARONI, F ;
RUSTICALI, AG ;
FESTI, D ;
SAPIO, C ;
RODA, E ;
BANTERLE, C ;
PUCI, A ;
FORMENTINI, F ;
COLASANTI, S ;
NARDIN, F .
HEPATOLOGY, 1987, 7 (05) :913-917
[6]  
BATESON MC, 1978, DIG DIS, V7, P623
[7]  
CAREY MC, 1978, J LIPID RES, V19, P945
[8]   Cholelithiasis and dietary risk factors - An epidemiologic investigation in Vidauban, Southeast France [J].
Caroli-bosc, FX ;
Deveau, C ;
Peten, EP ;
Delabre, B ;
Zanaldi, H ;
Hebuterne, X ;
Hastier, P ;
Viudes, F ;
Belanger, F ;
Caroli-Bosc, C ;
Harris, A ;
Hardion, M ;
Rampal, P ;
Delmont, JP .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (09) :2131-2137
[9]   Prevalence of cholelithiasis - Results of an epidemiologic investigation in Vidauban, southeast France [J].
Caroli-Bosc, FX ;
Deveau, C ;
Harris, A ;
Delabre, B ;
Peten, EP ;
Hastier, P ;
Sgro, E ;
Caroli-Bosc, C ;
Stoia, M ;
Demarquay, JF ;
Dumas, R ;
Coussement, A ;
Delmont, JP .
DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (07) :1322-1329
[10]   Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor [J].
Chapman, BA ;
Burt, MJ ;
Chisholm, RJ ;
Allan, RB ;
Yeo, KHJ ;
Ross, AG .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (02) :349-353